Abbvie Inc.

Walter and Eliza Hall Institute of Medical Research

Chang H Park

Le Wang

Michael D Wendt

Lisa A Hasvold

Andrew J Souers

Steven Elmore

George A Doherty

Xilu Wang

Zhi-Fu Tao

Aaron R Kunzer

Milan Bruncko

Gary T Wang

Gerard M Sullivan

Hong Ding

George S Sheppard

Xiaohong Song

William J McClellan

Robert A Mantei

Cheol-Min Park

Laura A Hexamer

Andrew M Petros

Keith F McDaniel

John K Pratt

Dachun Liu

Warren M Kati

Andrew Bogdan

William J Mcclellan

Steven W Elmore

Todd M Hansen

James H Holms

Yujia Dai

Guillaume Laurent Lessene

Robert Hubbard

Peter Edward Czabotar

Todd N Soltwedel

Chaohong Sun

Robert D Hubbard

Peter Malcom Colman

John H Holms

The present invention provides for compounds of formula (I) wherein Y, Y, R, R, R, A, A, A, and A, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Bromodomain inhibitors

The present invention provides for compounds of formula (I) wherein A, Y, J, R, R, and Rhave any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.

Isoindolone derivatives

The present invention provides for compounds of formula (I) wherein A, A, A, A, J, and Xhave any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.

Pyridinone and pyridazinone derivatives

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Growing community of inventors

Wadsworth, IL, United States of America

Chang H Park